Department of Medical Oncology, Ankara Oncology Hospital, Ankara, Turkey.
Med Oncol. 2011 Mar;28(1):391-6. doi: 10.1007/s12032-010-9450-2. Epub 2010 Feb 24.
We retrospectively analyzed 294 patients with primary soft tissue sarcoma followed between 1996 and 2002 in Ankara Oncology Hospital. There were 170 male and 124 female patients with the age range of 16-80 years. The primary tumor was in the extremity in 72.9% of the patients. We determined lung metastasis in 102 (85%) out of the 120 patients as distant metastasis. The most common adult sarcomas were liposarcoma (16.3%), malignant mesenchymal tumor (MMT) (13.9%), malignant fibrous histiocytoma (MFH) (11.2%), rhabdomyosarcoma (10.2%) and synovial sarcoma (10.2%). Seventeen patients (5.3%) had grade 1 tumor, 143 patients (52.2%) had grade 2 tumor, and 112 patients (41.4%) had grade 3 tumor. In 45 patients (15.3%), the grade of the tumors is unknown. The tumor size was 0 to <5 cm in 54 cases (19.4%), 5-10 cm in 117 cases (41.9%) and >10 cm in 108 cases (38.7%). In 15 cases (5.1%), tumor size was unknown. Ninety-five patients (32.4%) were treated with adjuvant chemotherapy, and 125 patients (42.7%)) were treated with palliative chemotherapy. Prognostic factors influencing the overall survival were tumor size, grade, adjuvant radiotherapy and chemotherapy. Adjuvant radiotherapy had influence on disease-free survival. While tumor grade and size showed a significant value for predicting local recurrence, grade, localization of tumor, adjuvant chemotherapy and radiotherapy had an impact on metastasis development. The 1-year overall survival for all patients was 73.4%, 3-year overall survival was 51.8%, and 5-year overall survival was 45.1%.
我们回顾性分析了 1996 年至 2002 年期间在安卡拉肿瘤医院就诊的 294 例原发性软组织肉瘤患者。患者中男 170 例,女 124 例,年龄 16-80 岁。原发性肿瘤位于四肢的患者占 72.9%。我们确定 120 例中有 102 例(85%)存在远处转移,即肺转移。最常见的成人肉瘤为脂肪肉瘤(16.3%)、恶性间叶组织肿瘤(MMT)(13.9%)、恶性纤维组织细胞瘤(MFH)(11.2%)、横纹肌肉瘤(10.2%)和滑膜肉瘤(10.2%)。17 例(5.3%)患者肿瘤分级为 1 级,143 例(52.2%)患者肿瘤分级为 2 级,112 例(41.4%)患者肿瘤分级为 3 级。45 例(15.3%)患者肿瘤分级未知。肿瘤大小为 0-<5cm 的患者 54 例(19.4%),5-10cm 的患者 117 例(41.9%),>10cm 的患者 108 例(38.7%)。15 例(5.1%)患者肿瘤大小未知。95 例(32.4%)患者接受辅助化疗,125 例(42.7%)患者接受姑息化疗。影响总生存的预后因素包括肿瘤大小、分级、辅助放疗和化疗。辅助放疗对无病生存有影响。肿瘤分级和大小对预测局部复发有显著意义,而分级、肿瘤定位、辅助化疗和放疗对转移发展有影响。所有患者的 1 年总生存率为 73.4%,3 年总生存率为 51.8%,5 年总生存率为 45.1%。